Envoy Medical Inc. Class A Common Stock (COCH)

FairStock Score: 21/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At the close on 2026-10-13, Mr. Market asks $0.66 per share for Envoy Medical, valuing the whole company at about $50.9 million. That is a rich price for a business that in fiscal 2025, the year ended December 31, 2025, reported revenue of only $241,000 and a net loss of $23.8 million, or diluted EPS of -$1.23. In fiscal Q2 2026, the quarter ended June 30, 2026, revenue was $51,000 and net loss was $6.0 million, or diluted EPS of -$0.07. Fiscal 2024, the year ended December 31, 2024, had revenue of $225,000 and a net loss of $20.8 million; fiscal 2023, the year ended December 31, 2023, had revenue of $316,000 and a net loss of $29.9 million. So revenue has shrunk, not compounded. FairStock's Lynch category is 'none' because the company lost money in each of the last four years. FairStock also calculates a price-to-book of 13.18, a trailing free cash flow of -$21.7 million, an FCF yield of -42.7%, and a ROCE of -86.53%. Debt to equity of 0.22 looks modest, but an Altman Z-score of -17.87 and Piotroski F-score of 3/9 suggest a fragile business, and the FairStock Score is 21/100. I see no durable moat: a 43-person firm with microscopic revenue and no profits has not proved pricing power or customer captivity. This is speculation on future medical-device adoption, not a Graham-style bargain.

In plain English: Envoy Medical is a hearing-health company that makes hearing aids and implantable hearing devices. It brings in very little revenue and loses millions of dollars each year, and it has not been profitable in the last four years. At $0.66 a share, the price looks expensive compared with the company's current sales, losses, and cash use, so the stock depends mostly on future hope.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer